HRP20150182T1 - Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa - Google Patents

Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa Download PDF

Info

Publication number
HRP20150182T1
HRP20150182T1 HRP20150182TT HRP20150182T HRP20150182T1 HR P20150182 T1 HRP20150182 T1 HR P20150182T1 HR P20150182T T HRP20150182T T HR P20150182TT HR P20150182 T HRP20150182 T HR P20150182T HR P20150182 T1 HRP20150182 T1 HR P20150182T1
Authority
HR
Croatia
Prior art keywords
antibody
use according
immunosuppressive drug
recipient mammal
inhibitor
Prior art date
Application number
HRP20150182TT
Other languages
English (en)
Croatian (hr)
Inventor
Russell P. Rother
Hao Wang
Zhen Zhong
Original Assignee
Alexion Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20150182(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals, Inc filed Critical Alexion Pharmaceuticals, Inc
Publication of HRP20150182T1 publication Critical patent/HRP20150182T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20150182TT 2006-03-02 2007-03-02 Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa HRP20150182T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77885906P 2006-03-02 2006-03-02
PCT/US2007/005290 WO2007103134A2 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity
EP07752018.7A EP1988882B1 (en) 2006-03-02 2007-03-02 Prolongation of survival of an allograft by inhibiting complement activity

Publications (1)

Publication Number Publication Date
HRP20150182T1 true HRP20150182T1 (hr) 2015-06-05

Family

ID=38475394

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150182TT HRP20150182T1 (hr) 2006-03-02 2007-03-02 Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa

Country Status (21)

Country Link
US (1) US20100135992A1 (cg-RX-API-DMAC7.html)
EP (2) EP2918269A1 (cg-RX-API-DMAC7.html)
JP (2) JP5722524B2 (cg-RX-API-DMAC7.html)
KR (2) KR101527225B1 (cg-RX-API-DMAC7.html)
CN (1) CN101437501B (cg-RX-API-DMAC7.html)
AU (1) AU2007224250B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0708424A2 (cg-RX-API-DMAC7.html)
CA (1) CA2644020C (cg-RX-API-DMAC7.html)
DK (1) DK1988882T3 (cg-RX-API-DMAC7.html)
ES (1) ES2530637T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150182T1 (cg-RX-API-DMAC7.html)
IL (1) IL193623A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008011054A (cg-RX-API-DMAC7.html)
NZ (1) NZ570802A (cg-RX-API-DMAC7.html)
PL (1) PL1988882T3 (cg-RX-API-DMAC7.html)
PT (1) PT1988882E (cg-RX-API-DMAC7.html)
RS (1) RS53864B1 (cg-RX-API-DMAC7.html)
RU (1) RU2445975C2 (cg-RX-API-DMAC7.html)
SG (1) SG171578A1 (cg-RX-API-DMAC7.html)
SI (1) SI1988882T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007103134A2 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
CA2662480C (en) * 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
BRPI0921237A2 (pt) 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
WO2010126898A1 (en) * 2009-04-27 2010-11-04 The Trustees Of The University Of Pennsylvania Methods for reducing the level of alloantibodies in a subject
CN102597005A (zh) * 2009-06-23 2012-07-18 阿雷克森制药公司 与补体蛋白质结合的双特异性抗体
WO2011003098A1 (en) * 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CN101621801B (zh) * 2009-08-11 2012-11-28 华为终端有限公司 无线局域网的认证方法、系统及服务器、终端
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP2709627B1 (en) * 2011-05-16 2020-09-23 Genzyme Corporation Induction of immune tolerance by using methotrexate
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
EP3290922A1 (en) 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
WO2015023972A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
HUE041809T2 (hu) * 2013-11-22 2019-05-28 Shire Viropharma Inc Eljárások antitest által közvetített kilökõdés kezelésére szervbeültetéses páciensekben C1-észteráz inhibitorral
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
US10968426B2 (en) 2015-05-08 2021-04-06 President And Fellows Of Harvard College Universal donor stem cells and related methods
WO2017075325A1 (en) * 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy
RU2742606C2 (ru) * 2015-12-18 2021-02-09 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
RU2018146847A (ru) * 2016-06-07 2020-07-09 Новартис Аг Тесидолумаб для применения в лечении отторжения трансплантата
US20190127453A1 (en) * 2016-06-07 2019-05-02 Novartis Ag An anti-c5 antibody dosing regimen
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
PT3658184T (pt) 2017-07-27 2023-11-29 Alexion Pharma Inc Formulações de anticorpo anti-c5 de elevada concentração
EP3700928A1 (en) 2017-10-26 2020-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
JP7520725B2 (ja) 2018-05-31 2024-07-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
EP4306128A3 (en) 2018-10-30 2024-03-27 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技（上海）有限公司 环孢菌素类似物及其用途
JP2022532174A (ja) 2019-05-10 2022-07-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 修飾多能性細胞
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2021068957A1 (en) 2019-10-12 2021-04-15 Farsight Medical Technology (Shanghai) Co., Ltd. Treatment and prevention of nephrotoxin-induced kidney injuries
WO2021146471A2 (en) * 2020-01-15 2021-07-22 The Regents Of The University Of California Transplanted cell protection via inhibition of polymorphonuclear cells
CN114245744A (zh) 2020-04-15 2022-03-25 睿诺医疗科技（上海）有限公司 器官损伤的预防和治疗
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
WO1992010205A1 (en) * 1990-12-06 1992-06-25 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
JP2002502824A (ja) * 1998-02-04 2002-01-29 ザ・ジェネラル・ホスピタル・コーポレイション 同種移植における補刺激遮断および混合キメラ現象
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6192891B1 (en) * 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
US6538028B1 (en) * 2000-02-01 2003-03-25 Vanderbilt University Method for inhibiting complement activation
PT1325033E (pt) 2000-10-10 2010-04-15 Genentech Inc Inibição da activação do complemento c5 para o tratamento e a prevenção da rejeição diferida de um xenoenxertos ou de uma rejeição vascular aguda
NZ529044A (en) * 2001-06-08 2008-03-28 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
JP4564261B2 (ja) * 2002-01-22 2010-10-20 ジェンザイム、コーポレーション 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
WO2004019891A2 (en) * 2002-08-28 2004-03-11 Sangstat Medical Corporation Methods and compostions for immune tolerance
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
DK1755674T3 (en) * 2004-05-14 2015-02-09 Alexion Pharma Inc PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
KR101527225B1 (ko) 2015-06-08
DK1988882T3 (en) 2015-02-23
AU2007224250A1 (en) 2007-09-13
CN101437501B (zh) 2012-09-05
IL193623A0 (en) 2009-08-03
SG171578A1 (en) 2011-06-29
PT1988882E (pt) 2015-02-17
KR20080098543A (ko) 2008-11-10
EP1988882A2 (en) 2008-11-12
RS53864B1 (sr) 2015-08-31
JP2009528369A (ja) 2009-08-06
RU2445975C2 (ru) 2012-03-27
RU2008139118A (ru) 2010-04-10
MX2008011054A (es) 2009-03-03
AU2007224250B2 (en) 2012-05-03
KR20140124023A (ko) 2014-10-23
CA2644020C (en) 2016-05-10
PL1988882T3 (pl) 2015-04-30
JP2013155202A (ja) 2013-08-15
WO2007103134A3 (en) 2008-09-12
WO2007103134A2 (en) 2007-09-13
BRPI0708424A2 (pt) 2011-05-31
HK1120444A1 (en) 2009-04-03
NZ570802A (en) 2012-03-30
US20100135992A1 (en) 2010-06-03
SI1988882T1 (sl) 2015-07-31
CN101437501A (zh) 2009-05-20
ES2530637T3 (es) 2015-03-04
EP2918269A1 (en) 2015-09-16
CA2644020A1 (en) 2007-09-13
KR101650264B1 (ko) 2016-08-22
EP1988882B1 (en) 2014-12-17
JP5722524B2 (ja) 2015-05-20

Similar Documents

Publication Publication Date Title
HRP20150182T1 (hr) Produžavanje preživljavanja transplantata inhibiranjem aktivnosti komplementa
Rostaing et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study
Pengel et al. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials
Hassan et al. Phytochemical constituents and biological activity of selected genera of family Crassulaceae: A review
NO20074497L (no) Synergistisk kombinasjon av xolair/omalizumab/E25 med immunsuppressivt middel
Liu et al. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis
JP2009528369A5 (cg-RX-API-DMAC7.html)
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
JP2010534243A5 (cg-RX-API-DMAC7.html)
CL2007003855A1 (es) Composicion que comprende un vehiculo sustrato y un deposito sobre dicho vehiculo sustrato, donde dicho deposito comprende particulas de un compuesto derivado de pregnano; capsula y tableta que la comprenden; y uso en el tratamiento de enfermedades t
CL2008002380A1 (es) Composicion farmaceutica de liberacion prolongada que comprende micofenolato sodico, al menos un material de control de liberacion y opcionalmente excipientes; y su uso en el tratamiento de enfermedades que requieren de inmunosupresores, tales como trasplantes, injertos o enfermedades autoinmunes.
Sadaka et al. Proteasome inhibition for antibody-mediated allograft rejection
Falagas et al. Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials
Tasaki et al. Bortezomib eliminates plasma cells from a renal graft in plasma cell–rich acute rejection
Sanders-Pinheiro et al. Excessive immunosuppression in kidney transplant patients: prevalence and outcomes
Gibelli et al. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: comparative study
Dupuis et al. Experience with low-dose valganciclovir prophylaxis in adult liver transplant recipients
Lee et al. Acute kidney injury resulting from Amanita neoovoidea intoxication
Poirier et al. Recombinant human C1-inhibitor inhibits cytotoxicity induced by allo-and xenoantibodies
Matia et al. The positive effect of immunosuppression on adaptation of venous allografts to arterialisation in rats
Wszola et al. Long term medical and economical benefit of machine perfusion (MP) kidney storage in comparison to cold storage (CS)
Emiroglu et al. Effect of amyloidosis on long-term survival in kidney transplantation
Santos et al. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience
Podshivalov Antifungal Prophylaxis After Liver Transplantation
Viganò et al. The role of basiliximab induction therapy in adult-to-adult living-related transplantation and deceased donor liver transplantation: a comparative retrospective analysis of a single-center series